Avelumab and Merkel Cell Carcinoma: Understanding Your Legal Rights in New Jersey

From General Health Awareness to Occupational Exposure

For decades, public health communication has centered on broad wellness principles and general disease prevention, often emphasizing lifestyle factors and routine screening. This legacy framework has served to educate populations about common health risks and the importance of medical vigilance. However, as industrial and pharmaceutical landscapes evolve, so too must the scope of health information. The transition from general health awareness to specific occupational and environmental exposures requires a careful shift in focus—one that acknowledges the complexity of modern chemical and biological agents encountered in professional settings. In the context of mass production environments, workers may come into contact with a range of substances whose long-term health implications are not always immediately apparent. Among these, exposure to certain therapeutic agents and their manufacturing byproducts has emerged as a distinct concern. Avelumab, a monoclonal antibody used in oncology, represents one such compound where occupational exposure during production or handling warrants attention. Specifically, the potential link between Avelumab exposure and the development of Merkel cell carcinoma—a rare but aggressive skin cancer—has prompted legal and regulatory scrutiny. This pivot from general health education to a targeted occupational risk assessment underscores the need for clear timelines regarding legal recourse, such as the statute of limitations for claims in New Jersey, where affected individuals may seek settlement for exposure-related harms.

Avelumab: Mechanism and Therapeutic Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often in older adults. Diagnosis is confirmed by histopathology and immunohistochemistry showing neuroendocrine differentiation. For patients with metastatic disease, immune checkpoint inhibition has significantly improved treatment outcomes, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Immune-Related Adverse Events and Risk Considerations

Avelumab's pharmacology involves blocking PD-L1, thereby enhancing T-cell-mediated antitumor immune responses. However, checkpoint inhibitors are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported adverse effects include hypercalcaemia secondary to reactivation of sarcoidosis, as described in a case report of a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). That patient's hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may include dermatitis, colitis, hepatitis, pneumonitis, and endocrinopathies, though specific incidence rates for avelumab in MCC are not detailed in the provided evidence. Mechanistic pathways linking avelumab to Merkel cell carcinoma are primarily therapeutic rather than causative. Avelumab is used to treat MCC by blocking PD-L1, which is often expressed on tumor cells and immune cells in the tumor microenvironment. This blockade prevents PD-L1 from binding to PD-1 on T cells, thereby restoring antitumor immune activity. The drug does not cause MCC; rather, it is a treatment for the disease. However, in patients who are refractory to avelumab, the tumor may evade immune detection through alternative mechanisms, such as upregulation of other immune checkpoints or loss of antigen presentation. For avelumab-refractory patients, combination therapy with ipilimumab and nivolumab has shown efficacy, with three out of five patients in one study responding according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG also reported that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Statute of Limitations for Avelumab Claims in New Jersey

Regarding risk anchors, the adequacy of warnings about avelumab and Merkel cell carcinoma is a critical consideration. The provided evidence does not include specific information on product labeling or warnings. However, given that avelumab is approved specifically for metastatic MCC, warnings likely focus on immune-related adverse events and the risk of progression despite treatment. For settlement-related considerations, affected patients may include those who experienced severe irAEs or disease progression while on avelumab. The timeline between exposure and documented harm varies: irAEs can occur weeks to months after starting treatment, while disease progression may be assessed at first restaging (typically 8-12 weeks). In the case of hypercalcaemia due to sarcoidosis reactivation, the event occurred during treatment and resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline to documented harm is defined by radiographic or clinical progression, which may occur within months of starting therapy. In New Jersey, the statute of limitations for product liability claims, including those related to pharmaceutical drugs, is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For avelumab-related claims, the clock may start at the time of diagnosis of an irAE or disease progression. Given the complexity of MCC and its treatment, affected patients should consult legal counsel to determine applicable deadlines. In summary, avelumab is a PD-L1 inhibitor approved for metastatic MCC, with a response rate of about one-third in chemotherapy-refractory patients. Immune-related adverse events, such as sarcoidosis reactivation, can occur during treatment. For patients who progress on avelumab, alternative immunotherapies like ipilimumab plus nivolumab may be effective. Settlement considerations should account for the timing of harm relative to treatment initiation and the adequacy of warnings provided to patients and prescribers.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Avelumab-related claims in New Jersey?

In New Jersey, the statute of limitations for product liability claims, including those related to pharmaceutical drugs, is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For Avelumab-related claims, the clock may start at the time of diagnosis of an immune-related adverse event or disease progression. It is important to consult with legal counsel to determine the applicable deadline for your specific case.

Can Avelumab cause Merkel cell carcinoma?

No, Avelumab is a treatment for Merkel cell carcinoma, not a cause. It is a PD-L1 inhibitor approved for metastatic MCC. However, patients may experience immune-related adverse events or disease progression while on therapy, which could be the basis for a legal claim if warnings were inadequate.

What are the common side effects of Avelumab?

Common immune-related adverse events include dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and reactivation of sarcoidosis leading to hypercalcaemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). These side effects can occur weeks to months after starting treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.